Systemic Lupus Erythematosus — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Response to letter regarding variants in the interferon regulatory factor 5 gene confer genetic risk for systemic lupus erythematosus in a Han Chinese population.
Xu Wenqi et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41841449/
- 2.
Treatment of discoid lupus erythematosus with crisaborole.
Dai Yingying et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41808655/
- 3.
Persistent cutaneous lupus erythematosus: A pathway toward systemic disease?
Wang Qi et al. — Journal of translational autoimmunity (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41869391/
- 4.
A novel epigenetic regulation of JAM-A by EZH2-DNMT3A cascade contributes to T cell adhesion via the activation of Rap1a in lupus patients.
Ding Lei et al. — Journal of translational autoimmunity (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41815940/
- 5.
GRN and KLRB1 define a shared peripheral-blood transcriptomic signature linking SLE and IPF.
Pang Lijun et al. — Journal of translational autoimmunity (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41782635/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Recruiting — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06133972
- 2.
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT06897930
- 3.
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07201558
- 4.
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Recruiting — Early Phase 1 — Noxopharm Limited
https://clinicaltrials.gov/study/NCT07072611
- 5.
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Recruiting — Phase 3 — AstraZeneca
https://clinicaltrials.gov/study/NCT06015737
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Systemic Lupus Erythematosus
Systemic lupus erythematosus (lupus) is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation affecting joints, skin, kidneys, and other organs. It predominantly affects women of childbearing age. While there is no cure, a growing range of treatments can manage the condition effectively.
Most Recent Research
Common Questions
What is Systemic Lupus Erythematosus?
Systemic lupus erythematosus (lupus) is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation affecting joints, skin, kidneys, and other organs. It predominantly affects women of childbearing age. While there is no cure, a growing range of treatments can manage the condition effectively.
How many clinical trials are available for Systemic Lupus Erythematosus?
RareWays currently indexes 1064 clinical trials for Systemic Lupus Erythematosus, of which 291 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Systemic Lupus Erythematosus come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Systemic Lupus Erythematosus.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.